Lung cancer poses a significant challenge as it is often diagnosed at advanced stages, leading to delays in treatment and reduced survival rates.
However, this is being challenged by the adoption of revolutionary next generation sequencing technology that enables Rapid Genomic Profiling (RGP), which is becoming more common in Australian pathology laboratories reporting clinically actionable targets so that physicians and patients can decide treatment options sooner.
This White Paper, authored by London Agency and commissioned by Thermo Fisher Scientific, explores RGP’s transformative potential for lung cancer patients in Australia.
Download the White Paper below
